None of us here ever said that Telix use of a PSA measure was a wise move, or not. They presented the data when it suited them. Others do too!
The 17 patients who had the best PSA drop are the same patients that had the longest OS. Not that correlation means the world, but there it is!
It would be scandalous if Telix decided to reject PSA as a measure of treatment effect and choose just OS simply because the do not like the results from their own sponsored trial (Nguyen et al).
In any case, Survival is a difficult measure to work with in these treatments so I am a bit surprised that you guys are so keen on it. How do you hope to prove therapeutic effect in a preregistrational study that is single arm, with an outcome measure where you have to wait for people to die, when the disease itself is chronic in nature. To my knowledge, this stuff comes under so called Phase 4 trials: real world evidence that come post approval of a treatment!
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)